Target intelligence / Profile preview

Neurotransmitter (null)

Target
null
Molecular classification
Amino acids (e.g., glutamate, GABA, glycine, aspartate), Biogenic amines (monoamines; e.g., dopamine, serotonin, norepinephrine, epinephrine, histamine), Peptides (e.g., substance P, endorphins, neuropeptide Y, vasopressin), Purines (e.g., adenosine, ATP), Gasotransmitters (e.g., nitric oxide), “Other” (e.g., acetylcholine, anandamide)
01

Overview

Neurotransmitters are endogenous chemical messengers that facilitate rapid signaling across synaptic gaps between neurons and other cells in the nervous system. They may be classified structurally as amino acids (e.g., glutamate, GABA), amines (e.g., dopamine, serotonin), peptides (e.g., substance P, endorphins), purines (e.g., ATP, adenosine), and gases (e.g., nitric oxide). These chemicals can be excitatory, inhibitory, or modulatory, regulating essential functions such as mood, attention, memory, movement, muscle control, and pain, and alterations in their pathways contribute to numerous neurological and psychiatric diseases.

Other names
chemical messengerbrain messengersignaling molecule in the nervous system
02

Mechanism of action

null for class; specific mechanisms depend on neurotransmitter (e.g., reuptake inhibition for SSRIs, receptor antagonism for antipsychotics, enzyme inhibition for cholinesterase inhibitors)

03

Biological functions

Signal transduction (main role; chemicals transmit signals between cells)Modulation of neural circuits (e.g., neuromodulation by neuropeptides, monoamines)Regulation of brain functions like learning, memory, mood, sleep, appetite, movement, muscle contractionExcitation and inhibition of neuronal activitySynaptic plasticity, neurodevelopment, pain signaling, autonomic function
04

Disease associations

Neurodegenerative disease (e.g., dopamine depletion in Parkinson’s)Psychiatric disorders (e.g., serotonin dysregulation in depression and anxiety, dopamine dysregulation in schizophrenia/addiction)Epilepsy/seizure disorders (modulation of excitatory/inhibitory balance)Sleep disorders, movement disorders, Alzheimer’s diseaseOther roles in pain syndromes, cardiovascular/autonomic disorders

Beyond the preview

Go deeper on Neurotransmitter (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurotransmitter (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call